[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100529881":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":28,"locations":29,"responsibleParty":42,"collaborators":28,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":28,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":28,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":28,"overallStatus":64,"whyStopped":28,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Bellus Health Inc. - a GSK company","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1","EXPERIMENTAL","10 Japanese and 8 Caucasian subjects. 8 out of 10 Japanese subjects will receive BLU-5937 Dose A and 2 will receive placebo. All Caucasian subjects will receive BLU-5937 Dose A.",[13],"Drug: BLU-5937",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2","8 Japanese subjects. 6 out of 8 will receive BLU-5937 Dose B and 2 will receive placebo.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Cohort 3","8 Japanese subjects. 6 out of 8 will receive BLU-5937 Dose C and 2 will receive placebo.",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","BLU-5937","Single and multiple doses assessment",[9,15,19],null,[30],{"facility":31,"status":28,"city":32,"state":28,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":28},"Richmond Pharmacology Ltd.","London","SE1 1YR","United Kingdom","UK",{"type":37,"coordinates":38},"Point",[39,40],-0.12574,51.50853,{"lat":40,"lon":39},{"type":43,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100529881","phase-1-evaluation-of-the-pharmacokinetics-and-safety-of-blu-5937-in-healthy-adult-japanese-and-caucasian-subjects-100529881",false,"NCT06179537","Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects","A Phase I, Double-Blind, Randomised, Adaptive-designed Study to Assess the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects Following Single and Multiple Oral Doses","Inclusion Criteria:\n\n* Healthy males or non-pregnant, non-lactating healthy females\n\nExclusion Criteria:\n\n* History of neurological, endocrine, cardiovascular, respiratory, haematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.",true,"ALL","18 Years","45 Years",{"count":56,"type":57},34,"ACTUAL","INTERVENTIONAL",[60],"PHASE1","This is a Phase I, Double-Blind, Randomised, Adaptive-designed Study to Assess the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects Following Single and Multiple Oral Doses",[63],"Healthy","COMPLETED","2023-12-19",{"date":67,"type":57},"2023-12-22",{"date":69,"type":57},"2021-08-06",{"date":71,"type":57},"2021-11-21",{"name":5,"class":6},1]